Dr. Chung-Gyu Park holds both an MD and a PhD from Seoul National University College of Medicine. During his post-doctoral research, he spent three years conducting research in Dr. Jeffrey Bluestone's laboratory at the University of Chicago and UCSF. After returning to South Korea, he became a faculty member at Seoul National University College of Medicine, where his research has covered various aspects of immunology, including immune tolerance, islet transplantation, and xenotransplantation. He has been a member of several professional organizations, including The American Association of Immunologists (AAI), The Korean Association of Immunologists (KAI), The Transplantation Society, The American Society of Transplantation, and The Korean Society for Transplantation. In addition, he has been a member of IXA since 2003 and served as an IXA councilor from 2012 to 2016. Furthermore, he held the position of President of the Korean Association of Immunologists from 2017 to 2018. His contributions to the field include the publication of over 180 scientific papers in SCI-indexed academic journals. Notable among these is the first proof-of-concept success in pig-to-nonhuman primate islet xenotransplantation, published in the American Journal of Transplantation. Additionally, his work on immune tolerance induction in humanized mice with a novel anti-ICAM1 mAb was featured in the Journal of Experimental Medicine. Dr. Park's extensive research in xenotransplantation began in 2006 when he became involved with the 'Xenotransplantation Research Center (XRC).' This center received sponsorship from the Ministry of Health and Welfare in Korea, with the primary objective of advancing the clinical implementation of pig-to-human xenotransplantation. Over the years, Dr. Park played a pivotal role in establishing a comprehensive platform for pig-to-nonhuman primate xenotransplantation. His responsibilities encompassed tasks such as porcine islet isolation, overseeing NHP facilities, and conducting immune monitoring. His efforts led to significant advancements in the realm of pre-clinical research on islet and cornea xenotransplantation. One of the major accomplishments during his directorship was obtaining approval for the clinical trial of pancreatic islet xenotransplantation using wild-type porcine adult islets from the Ministry of Health and Welfare of Korea on December 22, 2022. Currently, the process of recruiting patients for the clinical trial is underway, and the study on pig-to-nonhuman pancreatic islet transplantation using adult islets isolated from genetically modified pigs is in progress.